Lv1
32 积分 2022-06-11 加入
Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial
5小时前
待确认
B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE)
3天前
已完结
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
8天前
已完结
Sequential immunotherapy: towards cures for autoimmunity
8天前
已完结
Bispecific T cell engager therapy for refractory rheumatoid arthritis
9天前
已完结
免疫检查点调控在系统性红斑狼疮发病及治疗中的研究进展
10天前
已完结
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
10天前
已完结
Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus
13天前
已关闭
Achievable but elusive: LLDAS and DORIS remission in clinical trials of belimumab
13天前
已完结
2024 Chinese expert consensus on the use of biologic therapy for systemic lupus erythematosus
14天前
已完结
皖公网安备34019202002308
